MYD88 and diffuse large B-cell lymphoma: In order to address this issue, this study was conducted with the following aims: detect the presence of MYD88 and TP53 gene mutations and correlate these findings with clinical outcome, initial treatment response, overall survival, and progression-free survival in a cohort of 50 DLBCL patients.